Elite Journal of Medical Sciences. Volume 1 issue 1(2023), Pp. 51-62
https://epjournals.com/journals/EJMS

Ceruloplasmin and HIV-Associated Pulmonary Complications: A Review

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Pulmonary complications stand as significant challenges in individuals living with human immunodeficiency virus (HIV), contributing to heightened morbidity and mortality rates. Ceruloplasmin, a multifaceted glycoprotein renowned for its antioxidant properties, has garnered attention for its potential role in the pathogenesis and progression of HIV-associated pulmonary disorders. This review aims to comprehensively explore the involvement of ceruloplasmin in HIV-related pulmonary complications, delving into its impact on oxidative stress, inflammation, and lung function. Through its ferroxidase activity, ceruloplasmin facilitates the conversion of ferrous iron to ferric iron, thereby curbing the generation of harmful reactive oxygen species (ROS) and safeguarding lung tissues from oxidative damage. Moreover, ceruloplasmin's regulation in response to inflammatory stimuli underscores its significance in modulating lung inflammation and mitigating injury, offering potential avenues for therapeutic intervention in HIV-associated pulmonary complications. Chronic inflammation and immune dysregulation characteristic of HIV exacerbate oxidative stress within the lungs, culminating in tissue damage and compromised lung function. Leveraging ceruloplasmin's antioxidant properties may thus hold promise in mitigating oxidative lung injury and inflammation, thereby ameliorating the risk of pulmonary complications in HIV-infected individuals. Serum ceruloplasmin levels have emerged as potential biomarkers for assessing oxidative stress and predicting the risk of pulmonary complications, offering valuable insights into disease severity and prognosis.

Keywords: *Ceruloplasmin, HIV, Pulmonary Complications, Respiratory Disorders, Antioxidant Defense, Oxidative Stress, Inflammation, Lung Disease*

Citation: Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Pulmonary Complications: A Review. Elite Journal of Health Science, 2023; 1(1):51-62

Introduction

Pulmonary complications represent a significant burden in individuals living with human immunodeficiency virus (HIV), contributing to increased morbidity and mortality rates. HIV-associated pulmonary disorders encompass a wide spectrum of conditions, including opportunistic infections, non-infectious lung diseases, and complications of antiretroviral therapy (ART). These complications pose substantial challenges to clinical management and adversely impact the quality of life of affected individuals. Ceruloplasmin, a multifunctional glycoprotein with antioxidant properties, has emerged as a potential modulator of lung health in individuals living with HIV. Beyond its canonical functions in copper metabolism and iron homeostasis, ceruloplasmin plays a critical role in scavenging free radicals and mitigating oxidative stress within the lungs. Oxidative stress is implicated in the pathogenesis of various pulmonary disorders, including chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung diseases. Dysregulation of ceruloplasmin levels and activity may compromise antioxidant defenses, exacerbating oxidative lung injury and inflammation in HIV-infected individuals. The intricate interplay between ceruloplasmin, oxidative stress, and pulmonary complications in HIV infection underscores the significance of elucidating the role of ceruloplasmin in HIV-associated lung disease. Ceruloplasmin's antioxidant properties may confer protection against oxidative damage and inflammation within the lungs, potentially mitigating the risk of pulmonary complications in this vulnerable population. Moreover, dysregulation of ceruloplasmin expression and activity may serve as a biomarker for assessing oxidative stress and predicting the risk of pulmonary complications in HIV-infected individuals.[1-15]

This review aims to provide a comprehensive overview of the role of ceruloplasmin in HIV-associated pulmonary complications, synthesizing existing literature to elucidate its impact on oxidative stress, inflammation, and lung function. Additionally, the diagnostic, prognostic, and therapeutic implications of ceruloplasmin modulation in the management of HIV-related lung disease will be discussed.

Ceruloplasmin Function and Regulation

Ceruloplasmin, a copper-binding glycoprotein predominantly synthesized in the liver, plays a pivotal role in various physiological processes essential for maintaining cellular homeostasis and overall health. Its multifunctional nature underscores its significance in copper metabolism, iron homeostasis, antioxidant defense mechanisms, and inflammatory responses. Copper Metabolism: Ceruloplasmin serves as the principal copper transporter in the bloodstream, facilitating the distribution of copper ions from the liver to peripheral tissues. Copper is an essential micronutrient involved in numerous enzymatic reactions critical for cellular functions, including energy metabolism, neurotransmitter synthesis, and connective tissue formation. Ceruloplasmin ensures the efficient delivery of copper to target tissues, thereby supporting essential biological processes throughout the body. Iron Homeostasis: In addition to its role in copper transport, ceruloplasmin modulates iron metabolism through its ferroxidase activity. This enzymatic function facilitates the conversion of ferrous iron (Fe^2+) to its ferric form (Fe^3+), promoting the incorporation of iron into transferrin, the primary iron transport protein in the bloodstream. By enhancing iron binding

to transferrin, ceruloplasmin helps regulate systemic iron levels, preventing iron overload and associated toxicity.[16-25]

Antioxidant Defense Mechanisms: Ceruloplasmin exerts potent antioxidant effects, protecting cells and tissues from oxidative damage induced by free radicals and reactive oxygen species (ROS). As a ferroxidase enzyme, ceruloplasmin converts toxic ferrous ions (Fe^2+) into less reactive ferric ions (Fe^3+), thereby preventing the generation of harmful hydroxyl radicals through the Fenton reaction. This antioxidant function helps mitigate oxidative stress and oxidative damage, preserving cellular integrity and reducing the risk of oxidative stress-related diseases. Regulation: Ceruloplasmin synthesis and secretion are tightly regulated at both transcriptional and post-transcriptional levels. Hormonal factors, such as estrogen and growth hormone, play a role in regulating ceruloplasmin expression, with estrogen stimulating ceruloplasmin synthesis in the liver. Additionally, inflammatory mediators, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), can induce ceruloplasmin production in response to acute-phase reactions. Genetic polymorphisms in the ceruloplasmin gene (CP) may also influence ceruloplasmin levels and activity, potentially impacting individual susceptibility to copper-related disorders and oxidative stress-related diseases.[26-30]

Role of Ceruloplasmin in HIV-Associated Pulmonary Complications

The role of ceruloplasmin in HIV-associated pulmonary complications is an emerging area of interest, with growing evidence suggesting its involvement in the pathogenesis and progression of lung diseases in individuals living with HIV. Ceruloplasmin, beyond its classical functions in copper metabolism and antioxidant defense, plays a crucial role in modulating inflammatory responses, oxidative stress, and immune regulation within the lungs. Ceruloplasmin exerts potent antioxidant effects, scavenging free radicals and mitigating oxidative stress within the lungs. HIV infection is associated with increased oxidative stress due to the production of reactive oxygen species (ROS) by infected immune cells and chronic inflammation. Dysregulated oxidative stress contributes to lung injury, fibrosis, and impaired lung function in HIV-infected individuals. Ceruloplasmin's antioxidant properties may play a protective role against oxidative lung damage, potentially mitigating the risk of pulmonary complications. Ceruloplasmin modulates inflammatory responses within the lungs, influencing the balance between pro-inflammatory and anti-inflammatory mediators. HIV-associated pulmonary complications are characterized by chronic inflammation, immune dysregulation, and increased cytokine production. Ceruloplasmin's ability to regulate inflammatory pathways may impact the severity and progression of lung diseases in HIV-infected individuals. Dysregulation of ceruloplasmin levels or activity may exacerbate lung inflammation and contribute to the pathogenesis of respiratory complications.[31-40]

Ceruloplasmin plays a role in immune regulation and host defense mechanisms within the lungs. HIV infection leads to immune dysfunction, impairing the ability of the immune system to mount effective responses against pathogens and environmental insults. Ceruloplasmin's interactions with immune cells and cytokine signaling pathways may influence immune function and susceptibility to pulmonary infections in HIV-infected individuals. Dysregulated ceruloplasmin levels or activity may compromise immune responses, increasing the risk of respiratory infections and exacerbating

pulmonary complications. Ceruloplasmin may influence tissue remodeling processes within the lungs, including fibrosis and extracellular matrix deposition. HIV-associated pulmonary complications, such as HIV-associated pulmonary fibrosis (HIV-PF), are characterized by aberrant tissue remodeling and scarring in the lungs. Ceruloplasmin's role in modulating extracellular matrix turnover and fibrogenic pathways may contribute to the development and progression of pulmonary fibrosis in HIV-infected individuals.[41-45]

Diagnostic and Prognostic Implications

Diagnostic and prognostic implications of ceruloplasmin in HIV-associated pulmonary complications offer valuable insights into disease severity, progression, and treatment response, facilitating early detection, risk stratification, and personalized management strategies in affected individuals. Ceruloplasmin levels in serum or bronchoalveolar lavage fluid may serve as biomarkers for assessing oxidative stress within the lungs of HIV-infected individuals. Elevated ceruloplasmin levels may indicate increased oxidative burden and lung inflammation, correlating with the severity of pulmonary complications. Monitoring changes in ceruloplasmin levels over time could provide valuable information regarding disease progression and response to treatment. Ceruloplasmin levels may predict the risk of lung function decline and progression of pulmonary complications in HIV-infected individuals. Higher ceruloplasmin levels may be associated with greater lung injury, fibrosis, and impaired respiratory function. Monitoring ceruloplasmin levels longitudinally could help identify individuals at increased risk of developing severe pulmonary complications and guide early intervention strategies to mitigate lung damage. Ceruloplasmin levels may serve as prognostic indicators for clinical outcomes in HIV-associated pulmonary complications. Elevated ceruloplasmin levels may be predictive of poorer prognosis, increased risk of respiratory failure, and higher mortality rates in affected individuals. Integrating ceruloplasmin measurements into prognostic models may enhance risk stratification and inform clinical decision-making regarding treatment intensity and follow-up care. Changes in ceruloplasmin levels following therapeutic interventions, such as antiretroviral therapy (ART) or treatment for pulmonary complications, may reflect treatment response and efficacy. Decreases in ceruloplasmin levels post-treatment may indicate improvements in oxidative stress, inflammation, and lung function. Monitoring ceruloplasmin levels during treatment could help assess treatment response and guide adjustments to therapeutic regimens to optimize outcomes.[46-55]

Therapeutic Considerations

Therapeutic considerations regarding ceruloplasmin in the context of HIV-associated pulmonary complications encompass strategies aimed at modulating ceruloplasmin levels, targeting oxidative stress and inflammation, optimizing antiretroviral therapy (ART), and addressing underlying lung pathology to improve respiratory outcomes in affected individuals. Pharmacological interventions targeting ceruloplasmin expression or activity may offer therapeutic potential for managing HIV-associated pulmonary complications. Agents that enhance ceruloplasmin synthesis or stabilize its enzymatic activity could mitigate oxidative lung injury and inflammation, thereby improving lung function and reducing the risk of respiratory exacerbations. Further research is warranted to identify and evaluate ceruloplasmin-targeted therapies for their efficacy and safety in clinical

settings. Antioxidant therapy represents a promising approach for mitigating oxidative stress and lung inflammation in HIV-infected individuals with pulmonary complications. Antioxidant supplements, such as vitamins C and E, N-acetylcysteine (NAC), and alpha-lipoic acid, may augment endogenous antioxidant defenses and scavenge free radicals within the lungs. By reducing oxidative damage and inflammation, antioxidant therapy could alleviate respiratory symptoms and improve lung function in affected individuals.[56-60]

Anti-inflammatory agents, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), may be beneficial for managing lung inflammation and immune dysregulation in HIV-associated pulmonary complications. These agents can suppress inflammatory cytokine production, attenuate immune-mediated lung injury, and improve respiratory symptoms. However, careful consideration of potential side effects and drug interactions is necessary when using anti-inflammatory therapies in HIV-infected individuals. Optimizing ART regimens to minimize pulmonary toxicity and drug interactions is essential for managing HIV-associated pulmonary complications. Antiretroviral medications with favorable lung penetration and pulmonary safety profiles should be selected to minimize the risk of respiratory adverse effects and optimize treatment tolerability. Close monitoring of ART adherence and virologic suppression is crucial for preventing disease progression and minimizing the risk of pulmonary exacerbations. Pulmonary rehabilitation programs, including exercise training, respiratory therapy, and education, play a vital role in improving lung function, exercise capacity, and quality of life in individuals with HIV-associated pulmonary complications. These multidisciplinary interventions can enhance respiratory muscle strength, optimize oxygenation, and promote pulmonary hygiene, thereby reducing respiratory symptoms and enhancing functional status in affected individuals. Addressing comorbid medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, and pulmonary infections, is integral to comprehensive care for HIV-infected individuals with pulmonary complications. Coordinated multidisciplinary management involving pulmonologists, infectious disease specialists, and respiratory therapists is essential for optimizing treatment outcomes and minimizing the impact of comorbidities on respiratory health.[61-71]

Conclusion

Ceruloplasmin emerges as a promising player in the management of HIV-associated pulmonary complications, offering insights into oxidative stress modulation, inflammation, and lung function regulation. The multifaceted roles of ceruloplasmin underscore its significance in preserving respiratory health and mitigating the risk of pulmonary exacerbations in individuals living with HIV. By understanding the diagnostic, prognostic, and therapeutic implications of ceruloplasmin in HIV-associated pulmonary complications, clinicians can develop more targeted and personalized management strategies to optimize respiratory outcomes in affected individuals. Monitoring ceruloplasmin levels may serve as a valuable tool for assessing disease severity, progression, and treatment response, facilitating early intervention and risk stratification.

References

1. Vachon ML, Perumalswami P, Dieterich DT. Hepatobiliary manifestations of human immunodeficiency virus. Schiff's Diseases of the Liver. 2011:1060-1082.
2. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Substance use & misuse. 2006;41(10-12):1395-1463.
3. Kuczkowski KM. Human immunodeficiency virus in the parturient. Journal of clinical anesthesia. 2003;15(3):224-233.
4. Perovic O, Singh A. Nosocomial Infections in patients with human immunodeficiency virus (HIV). In HIV Infection in the Era of Highly Active Antiretroviral Treatment and Some of Its Associated Complications 2011. IntechOpen.
5. Cordie A, Gaber Y, AbdAllah M, Vergori A, Kharono B, Omran S, Afify S, Karkouri M, Chakroun M, Musa S, Moorhouse M. Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. Arab Journal of Gastroenterology. 2021;22(2):75-87.
6. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
8. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
10. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
11. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
12. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.

14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
15. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
16. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
17. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
18. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
19. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
20. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
21. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
22. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf

23. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
24. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
25. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
26. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
27. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
29. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
30. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
31. Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics. 2016;8(9):887-905.
32. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis. 2006;187(2):238-250.
33. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.

34. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
35. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
36. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
37. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
38. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
39. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
40. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
41. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
42. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.

43. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
44. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
45. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
46. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
47. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
48. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
49. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
50. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
51. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
52. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
53. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.

54. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
55. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
56. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
57. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
58. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
59. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
60. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
61. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
62. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
63. Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future science OA. 2017;4(1): FSO250.
64. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
65. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
66. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.

67. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
68. Ianiro G, Niro A, Rosa L, Valenti P, Musci G, Cutone A. To Boost or to Reset: The Role of Lactoferrin in Energy Metabolism. International Journal of Molecular Sciences. 2023;24(21):15925.
69. Bavaro DF, Laghetti P, Poliseno M, De Gennaro N, Di Gennaro F, Saracino A. A step closer to the "Fourth 90": A practical narrative review of diagnosis and management of nutritional issues of people living with HIV. Diagnostics. 2021;11(11):2047.
70. Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Hepatobiliary Disorders: A Review. Elite Journal of HIV, 2023; 1(1): 43-54
71. Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Psychiatric Disorders: A Review. Elite Journal of Laboratory Medicine, 2023; 1(1): 43-53